On June 28, 2022 Indianapolis-based Community Health Network and GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, reported a partnership to offer Galleri, GRAIL’s multi-cancer early detection (MCED) blood test, to individuals at Community Health Network’s sites of care (Press release, Grail, JUN 28, 2022, View Source [SID1234616340]). Community Health Network, central Indiana’s leading integrated healthcare system with more than 200 sites of care, will be the first healthcare system to offer the Galleri test to patients in its area.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through the partnership, Community Health Network will provide the Galleri test to individuals at elevated risk for cancer, including those over the age of 50. The test will be offered to eligible individuals through their primary care providers at select Community Health Network sites as a complement to existing single cancer screenings.

"As a health network committed to exceptional care for patients, and through the generous support of the Community Health Network’s Foundation, we are excited to be the first healthcare system in central Indiana to provide the Galleri test to patients as part of our network’s full continuum of services," said Patrick McGill, M.D., executive vice president and chief transformation officer at Community Health Network. "MCED tests like Galleri represent cutting-edge innovation that, along with appropriate screenings and care, can give patients diagnosed with cancer in our communities the best chance for successful outcomes."

The Galleri test is a first-of-its-kind MCED blood test. In a clinical study, the Galleri test demonstrated the ability to detect a shared signal from more than 50 types of cancers, over 45 of which lack recommended screening tests today. Using advanced genomics and machine learning, the test also determines the origin of the cancer signal, which can then guide diagnostic workup. Early detection of cancer can improve cancer outcomes, yet today, many cancers are detected in late stages because only five cancer types have recommended screenings – breast, cervical, colon, lung and prostate cancers.

"Healthcare systems are increasingly looking for ways to better meet patient needs, and the Galleri test – which can be administered with a simple blood draw as a complement to other cancer screenings – has the potential to screen for more cancers at earlier stages when there is a better chance for successful treatment," said Bob Ragusa, chief executive officer at GRAIL. "The status quo in cancer screening is simply unacceptable and using Galleri to complement existing screening approaches offers the potential to improve cancer detection in the population and improve public health."